Dow component Merck is within 2% of a new all-time high, after rallying 7.30% in the past month.Merck’s recent rise follows a couple of positive developments in October surrounding a high-blood-pressure treatment and a skin cancer vaccine.Merck reports its third quarter on October 27, with Wall Street eyeing earnings of $1.68 per share on revenue of $14.28 billion.Dow component Merck (NYSE:MRK) is within 2% of a new all-time high, after rallying 7.30% in the past month. Shares closed Tuesday at $94.61, up $0.49, or 0.52% in volume that was 13% heavier than normal. Q3 2022 hedge fund letters, c…